Literature DB >> 19373467

Chronic catastrophic-like antiphospholipid syndrome: a “smoldering” variant?

Daniel Athanazio1, Maria Cristina Rocha, Túlio Geraldo de Souza e Souza, Natália Oliveira e Silva, Sérgio Jezler, Mittermayer Barreto Santiago.   

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is characterized by life-threatening diffuse thrombotic manifestations involving particularly small vessels of kidney, lungs, brain and skin. We report a 20-year-old female with systemic lupus erythematosus and secondary antiphospholipid syndrome who presented typical organ and histological involvement as seen in CAPS but with protracted course suggesting a “smoldering” form of the disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373467     DOI： 10.1007/s00296-009-0913-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  10 in total

Review 1.  Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review.

Authors:  Kevin D Deane; Sterling G West
Journal:  Semin Arthritis Rheum       Date:  2005-12       Impact factor: 5.532

2.  Relapsing catastrophic antiphospholipid syndrome: report of three cases.

Authors:  Ronald A Asherson; Gerard Espinosa; Solomon Menahem; Janet Yinh; Silvia Bucciarelli; Xavier Bosch; Ricard Cervera
Journal:  Semin Arthritis Rheum       Date:  2007-10-30       Impact factor: 5.532

3.  Antiphospholipid syndrome nephropathy in systemic lupus erythematosus.

Authors:  Eric Daugas; Dominique Nochy; Du Le Thi Huong; Pierre Duhaut; Hélène Beaufils; Valérie Caudwell; Jean Bariety; Jean-Charles Piette; Gary Hill
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

Review 4.  Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome.

Authors:  M R Zamora; M L Warner; R Tuder; M I Schwarz
Journal:  Medicine (Baltimore)       Date:  1997-05       Impact factor: 1.889

Review 5.  Pulmonary manifestations in antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich
Journal:  Autoimmun Rev       Date:  2006-03-03       Impact factor: 9.754

6.  Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar.

Authors:  M Santiago; R Martinelli; A Ko; E A Reis; R D Fontes; E G Nascimento; S Pierangeli; R Espinola; A Gharavi
Journal:  Clin Exp Rheumatol       Date:  2001 Jul-Aug       Impact factor: 4.473

Review 7.  Antiphospholipid syndrome and the kidneys.

Authors:  Imad Uthman; Munther Khamashta
Journal:  Semin Arthritis Rheum       Date:  2006-06       Impact factor: 5.532

8.  The intrarenal vascular lesions associated with primary antiphospholipid syndrome.

Authors:  D Nochy; E Daugas; D Droz; H Beaufils; J P Grünfeld; J C Piette; J Bariety; G Hill
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

Review 9.  Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management.

Authors:  R J Green; S J Ruoss; S A Kraft; S R Duncan; G J Berry; T A Raffin
Journal:  Chest       Date:  1996-11       Impact factor: 9.410

Review 10.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.